

In the Claims:

- 1. (original) A prodrug for use in the treatment of physiological conditions comprising a carrier moiety selected from the group comprising cinnamoyl, benzoyl, phenylacetyl,
- 3,4-methylenedioxycinnamoyl and 3,4,5-trimethoxycinnamoyl, wherein the carrier moiety is chemically linked to a therapeutic polypeptide of the general formula aa_n , where aa is an amino acid or a chemical or structural variation thereof, where n is an integer from 2 to 10, and wherein the polypeptide is poorly absorbed orally.
- 2. (original) The prodrug of claim 1, wherein n is an integer from 3 to 6.
- 3. (original) The prodrug of claim 1, wherein n is 5.
- 4. (original) The prodrug of claim 1, wherein the polypeptide is Tyr-Gly-Gly-Phe-Met.
- 5. (original) The prodrug of claim 1, wherein the prodrug further comprises a non-therapeutic linker species linking the polypeptide to the carrier species.
- 6. (original) The prodrug of claim 5, wherein the linker species is an amino acid.
- 7. (original) A pharmaceutical composition comprising a carrier moiety selected from the group comprising cinnamoyl, benzoyl, phenylacetyl, 3,4 methylenedioxycinnamoyl and 3,4,5-trimethoxycinnamoyl chemically linked to a therapeutic polypeptide of the general formula aa_n , where aa is an amino acid or a chemical structural variation thereof, where n is an integer from 2 to 10, wherein the polypeptide is poorly absorbed orally, and a pharmaceutically effective adjuvant species.
- 8. (withdrawn) A method for enhancing the oral availability of therapeutic polypeptides of the general formula aa_n , where aa is an amino acid or a chemical or structural variation thereof, where n is an integer from 2 to 10, and wherein the polypeptide is poorly absorbed orally, wherein the method comprises the steps of chemically linking the polypeptide to a carrier moiety selected from the group comprising cinnamoyl, benzoyl, phenylacetyl, 3,4-methylenedioxycinnamoyl and 3,4,5-trimethoxycinnamoyl to form a prodrug.
- 9. (withdrawn) The method of claim 8, wherein the polypeptide is chemically linked to the carrier moiety through a non-therapeutic linker species.
- 10. (withdrawn) The method of claim 9, wherein the linker species is an amino acid.

- 11. (withdrawn) A method for the treatment of a physiological condition through the oral administration of a therapeutically effective species comprising the steps of:
 - a.) chemically linking a therapeutic polypeptide of the general formula aa_n , where aa is an amino acid or a chemical or structural variation thereof, where n is an integer from 2 to 10, and wherein the polypeptide is poorly absorbed orally, to a carrier moiety selected from the group comprising cinnamoyl, benzoyl, phenylacetyl, 3,4-methylenedioxycinnamoyl and 3,4,5-trimethoxycinnamoyl to form a drug; and
 - b.) orally administering the prodrug to a patient exhibiting the physiological condition.
- 12. (withdrawn) The method of claim 11, wherein the polypeptide is chemically linked to the carrier moiety through a non-therapeutic linker species.
- 13. (withdrawn) The method of claim 12, wherein the linker species is an amino acid.
- 14. (withdrawn) A method for the controlled release administration of a therapeutically effective polypeptide of the general formula aa_n , where aa is an amino acid or a chemical or structural variation thereof, where n is an integer from 2 to 10, and wherein the polypeptide is poorly absorbed orally, comprising the steps of:
- a.) chemically linking a carrier moiety selected from the group comprising cinnamoyl, benzoyl, phenylacetyl, 3,4-methylenedioxycinnamoyl and 3,4,5-trimethoxycinnamoyl to form a drug; and
 - b.) orally administering the prodrug to a patient.
- 15. (withdrawn) The method of claim 14, wherein the polypeptide is chemically linked to the carrier moiety through a non-therapeutic linker species.
- 16. (withdrawn) The method of claim 15, wherein the linker species is an amino acid.

12 17. (1

17. (new) The prodrug of claim 1, wherein the prodrug is cinnamoyl-Tyr-Gly-Gly-Phe-Met-).

18. (new) The prodrug of claim 1, wherein the carrier is cinnamoyl.